JP2010536797A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536797A5
JP2010536797A5 JP2010521229A JP2010521229A JP2010536797A5 JP 2010536797 A5 JP2010536797 A5 JP 2010536797A5 JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010521229 A JP2010521229 A JP 2010521229A JP 2010536797 A5 JP2010536797 A5 JP 2010536797A5
Authority
JP
Japan
Prior art keywords
formulation
rapamycin
ethanol
human subject
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010521229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/073520 external-priority patent/WO2009023877A2/en
Publication of JP2010536797A publication Critical patent/JP2010536797A/ja
Publication of JP2010536797A5 publication Critical patent/JP2010536797A5/ja
Pending legal-status Critical Current

Links

JP2010521229A 2007-08-16 2008-08-18 眼の疾患または状態を治療するための製剤 Pending JP2010536797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96525807P 2007-08-16 2007-08-16
US96528207P 2007-08-16 2007-08-16
PCT/US2008/073520 WO2009023877A2 (en) 2007-08-16 2008-08-18 Formulations for treatment of ocular diseases or conditions

Publications (2)

Publication Number Publication Date
JP2010536797A JP2010536797A (ja) 2010-12-02
JP2010536797A5 true JP2010536797A5 (enExample) 2013-07-25

Family

ID=40351498

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521229A Pending JP2010536797A (ja) 2007-08-16 2008-08-18 眼の疾患または状態を治療するための製剤

Country Status (6)

Country Link
EP (1) EP2187743B1 (enExample)
JP (1) JP2010536797A (enExample)
KR (1) KR20100055482A (enExample)
CN (1) CN101827523A (enExample)
ES (1) ES2507078T3 (enExample)
WO (1) WO2009023877A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
BR112014008759A8 (pt) * 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
CN103239399B (zh) * 2013-05-30 2016-06-29 山东兴瑞生物科技有限公司 一种西罗莫司纳米混悬剂及其制备方法
KR101674457B1 (ko) * 2013-11-04 2016-11-09 아주대학교산학협력단 다사티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물
KR20240023714A (ko) * 2015-02-02 2024-02-22 산텐 세이야꾸 가부시키가이샤 폴리아프론 및 이의 안검 투여
US11090296B2 (en) 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
JP6541124B2 (ja) * 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
MX393608B (es) * 2015-09-18 2025-03-24 Santen Pharmaceutical Co Ltd Profilactico o agente terapeutico para queratitis fungica.
US11400080B2 (en) 2016-05-25 2022-08-02 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
US10668011B2 (en) * 2016-06-30 2020-06-02 Durect Corporation Depot formulations
KR20190110101A (ko) * 2016-12-27 2019-09-27 더 유니버시티 오브 유타 리서치 파운데이션 안구내 약물 전달 장치 및 관련 방법들
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
EP3501496A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Liquid delivery composition
JP7365409B2 (ja) 2018-06-28 2023-10-19 エイアールエックス エルエルシー 溶解性単位用量膜構造物を製造するための分配方法
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN109431997B (zh) * 2018-12-20 2021-06-04 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法
US20230055121A1 (en) * 2019-12-26 2023-02-23 Santen Pharmaceutical Co., Ltd. Aqueous suspension composition containing sirolimus or salt thereof
CN112263670A (zh) * 2020-10-22 2021-01-26 温州医科大学 硼替佐米及其制剂在制备治疗脉络膜新生血管性相关疾病药物上的应用及滴眼液制备方法
EP4355349A4 (en) * 2021-06-15 2025-04-16 ONL Therapeutics, Inc. Methods and compositions for treating eye diseases and disorders
CN115337263B (zh) * 2022-08-09 2023-10-03 江苏汉晨药业有限公司 一种盐酸洛美沙星滴眼液
CN115813863A (zh) * 2022-12-15 2023-03-21 广州因明生物医药科技股份有限公司 一种可自发团聚的微球及其制备方法
CN119258216A (zh) * 2023-07-05 2025-01-07 沈阳兴齐眼药股份有限公司 眼用药物组合物、其制备方法、含其的眼用药盒及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
DK1539157T3 (da) * 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2010536797A5 (enExample)
Casson Medical therapy for glaucoma: A review
Lanier et al. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations
JP6629840B2 (ja) 眼の疾患および障害を処置するための化合物
EP3463315B1 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
Moisseiev et al. Drug delivery to the posterior segment of the eye
US9161923B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
EP2309980A1 (en) Ophthalmic compositions for treating pathologies of the posterior segment of the eye
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
US20090118262A1 (en) Non-Aqueous Water-Miscible Materials as Vehicles for Drug Delivery
TW201408287A (zh) 用於預防及／或治療乾眼症之組成物、方法及／或裝置
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
Rupenthal et al. progress in ocular drug delivery: challenges and constraints
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
AU2019208350A1 (en) Suspension compositions of multi-target inhibitors
MX2011005586A (es) Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
Kiernan et al. Topical drug delivery for posterior segment disease
CN103826631A (zh) 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
Fedorchak Barriers to Glaucoma Drug Delivery and Resolving the Challenges Using Nanotechnology
HK40092417A (zh) 用於治疗眼科疾病和障碍的化合物
HK40000005B (zh) 使用尼达尼布改善青光眼手术成功情况的组合物和方法